Inhibrx
INBX
102 hedge funds and large institutions have $354M invested in Inhibrx in 2025 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 22 increasing their positions, 35 reducing their positions, and 11 closing their positions.
137% more capital invested
Capital invested by funds: $149M → $354M (+$205M)
127% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 11
16% more funds holding
Funds holding: 88 → 102 (+14)
0.38% more ownership
Funds ownership: 72.09% → 72.47% (+0.38%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
37% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 35
61% less call options, than puts
Call options by funds: $784K | Put options by funds: $1.99M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$10.2M |
| 2 |
PA
Perceptive Advisors
New York
|
+$8.61M |
| 3 |
CP
Caligan Partners
New York
|
+$5.82M |
| 4 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$3.53M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$1.41M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$8.03M |
| 2 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.61M |
| 3 |
CM
Caption Management
Oklahoma City,
Oklahoma
|
-$4.53M |
| 4 |
SC
Slotnik Capital
Dallas,
Texas
|
-$3.51M |
| 5 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.26M |
INBX Hedge Fund Activity: Q3 2025 in Review
102 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Inhibrx (INBX) for Q3 2025, worth a combined $354M — up 137% from $149M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new INBX positions and 11 closed out — a net gain of 14 holders — while 22 added to existing stakes and 35 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $10.2M. The largest seller was Woodline Partners, cutting an estimated $8.03M.
- 102 institutional investors held Inhibrx (INBX) as of Q3 2025, up from 88 in Q2 2025.
- Funds reported $354M of Inhibrx stock for Q3 2025, up 137% quarter-over-quarter.
- 25 funds opened new Inhibrx positions in Q3 2025 and 11 closed out, a net change of +14 holders.
- The largest Inhibrx buyer in Q3 2025 was Morgan Stanley, an estimated $10.2M added.
- The largest Inhibrx seller in Q3 2025 was Woodline Partners, an estimated $8.03M sold.
Based on aggregated 13F filings for Q3 2025.